TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04749251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure management
Description: During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood pressure management
Description: During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
Study: NCT03344276

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessments
Description: Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessments
Description: Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurements of inflammatory biomarkers
Description: Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurements of inflammatory biomarkers
Description: Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
Study: NCT06010277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
Study: NCT05100888

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Theta-burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Theta-burst stimulation
Study: NCT05880706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets
Description: Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
Study: NCT06088459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1mg NWRD06 administered by electroporation
Description: DNA plasmid delivered via IM injection + electroporation using TERESA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4mg NWRD06 administered by electroporation
Description: DNA plasmid delivered via IM injection + electroporation using TERESA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8mg NWRD06 administered by electroporation
Description: DNA plasmid delivered via IM injection + electroporation using TERESA device
Study: NCT05042908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-003 Injection
Description: LBL-003 was given every two weeks for treatment
Study: NCT05807529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2ccPA
Description: 2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29
Study: NCT05039216

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 tubes of 7 mL will be sampled

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 tubes of 7 mL will be sampled
Study: NCT06310356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre 3
Description: CGM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer
Description: SMBG
Study: NCT06161519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038
Description: PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038
Description: PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
Study: NCT05900180

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Therapy
Description: Delivery of speech therapy services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Delivery of speech therapy services
Study: NCT06525740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06457451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIAPASOM program
Description: A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized dietetic care by a dietician for one year.
Study: NCT05946187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apolo_Bari Stepped-care intervention
Description: Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual for Bariatric Surgery
Description: Treatment as Usual for bariatric surgery in portuguese public hospitals.
Study: NCT04212637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Examine BOLD activity in relation to eye movements measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Examine BOLD activity in relation to eye movements measures
Study: NCT06184126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset and Hand-Held Controllers
Description: Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset and Hand-Held Controllers
Description: Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blindfolding and Noise Cancelling
Description: Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
Study: NCT06441877

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is an observationnal study.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is an observationnal study.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is an observationnal study.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is an observationnal study.
Study: NCT05246527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 30 min of cycling on an ergometer, moderate or high intensity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: 30 min of watching a movie
Study: NCT06452225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Plane Block
Description: Patients will receive external oblique intercostal plane block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: Patients will receive ultrasound guided transversus abdominis plane block.
Study: NCT06308887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 0.5 mg/5 ml of triamcinolone acetonide was injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 5 ml of 5% dextrose was injected.
Study: NCT05961787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)
Description: Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)
Description: Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)
Study: NCT06338930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
Study: NCT06476379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Testicular sperm extraction (TESE)
Description: Surgical procedure used to retrieve sperm directly from the testicles of men who have low sperm production or no sperm in their ejaculate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculate
Description: Ejaculate processing for ICSI
Study: NCT05056857

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical charts are reviewed
Study: NCT06352099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement with micronised diosmin, hesperidin and herbal extracts
Description: Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement with micronised diosmin, hesperidin and herbal extracts
Description: Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
Study: NCT05452304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
Study: NCT06226324

Intervention type: OTHER
Intervention: neuropsychological test
Description: The subjects were evaluated for memory, cognition, mood and sleep

Intervention type: OTHER
Intervention: neuropsychological test
Description: The subjects were evaluated for memory, cognition, mood and sleep

Intervention type: OTHER
Intervention: neuropsychological test
Description: The subjects were evaluated for memory, cognition, mood and sleep
Study: NCT04682743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: received intravenous one gram of paracetamol over a 15-minute period,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: received intravenous 8 mg of ondansetron over a 15-minute period.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: received intravenous 0.9% normal saline over a 15-minute period.
Study: NCT04361851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Experimental
Study: NCT04627779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preemptive analgesia with flurbiprofen axetil
Description: give flurbiprofen axetil 15 min before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preemptive analgesia with flurbiprofen axetil
Description: give flurbiprofen axetil 15 min before surgery
Study: NCT06017843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camps site selection for active case finding for TB using MATCH-AI
Description: The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
Study: NCT06633003

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antrodia cinnamomea Products
Description: Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antrodia cinnamomea Products
Description: A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products
Study: NCT05187364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE
Description: The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
Study: NCT05816226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2.5%
Description: Applied four times daily to TMJ with arthralgia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 1% topical
Description: Applied four times daily to TMJ with arthralgia
Study: NCT05560243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco cessation
Description: Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
Study: NCT06130280

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Description: 40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
Study: NCT06270108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 50mg twice daily (100mg total daily) for 56 days.
Study: NCT06281561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
Study: NCT04849793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Before starting the application, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. . The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes
Study: NCT05098873

Intervention type: OTHER
Intervention: psychodynamic
Description: intervention with adolescents through the presentation of questions to be completed

Intervention type: OTHER
Intervention: psychodynamic
Description: intervention with adolescents through the presentation of questions to be completed
Study: NCT06277674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab plus Pemetrexed and Anlotinib
Description: Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.